Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30458922.
- Also identified by DOI 10.1016/j.ophtha.2018.05.014 and PMC identifier 6538052.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti-IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.
Medical subject headings
- Autoimmune Diseases
- Biological Therapy
- Interleukin-23
- Uveitis